Welcome to our dedicated page for MetaVia news (Ticker: MTVA), a resource for investors and traders seeking the latest updates and insights on MetaVia stock.
MetaVia Inc. (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on cardiometabolic diseases, and its news flow centers on the development of two key product candidates: DA-1726 for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and vanoglipel (DA-1241) for MASH and type 2 diabetes. Company announcements frequently highlight clinical trial progress, new data readouts, and regulatory or listing updates that are relevant to investors and healthcare professionals following obesity and liver disease therapeutics.
News about DA-1726 includes Phase 1 multiple ascending dose results in obese but otherwise healthy adults, pharmacokinetic data supporting once-weekly subcutaneous dosing, and extended 8-week dosing cohorts at 48 mg. MetaVia has reported statistically significant weight loss, reductions in waist circumference, improvements in fasted glucose, and reductions in liver stiffness as measured by vibration-controlled transient elastography (VCTE), along with a favorable safety and tolerability profile. The company also releases updates on scientific presentations at meetings such as ObesityWeek, where DA-1726 data are shared with the medical community.
For vanoglipel (DA-1241), MetaVia’s news coverage includes Phase 2a trial results in presumed MASH patients, showing clinically meaningful reductions in glycated hemoglobin (HbA1c), improvements in liver inflammation and fibrosis markers, better liver steatosis and stiffness measures, and favorable shifts in plasma lipidomic profiles. The company announces poster presentations at major conferences such as the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, where detailed hepatic and metabolic data are presented.
In addition to clinical data, MetaVia issues news on corporate and capital market developments, including its 1-for-11 reverse stock split and communications regarding compliance with Nasdaq’s minimum bid price requirement. Readers of the MTVA news page can expect updates on trial milestones, conference presentations, research collaborations, and listing status, providing a consolidated view of MetaVia’s progress in cardiometabolic and liver disease drug development.
MetaVia (Nasdaq: MTVA) reported positive AI-modeling results from its Syntekabio collaboration, where Syntekabio's DeepMatcher® platform identified inflammatory, cardiometabolic, and cancer-related target pathways for MetaVia's oral GPR119 agonist vanoglipel (DA-1241). The analysis supports MetaVia's focus on MASH and potential type 2 diabetes.
MetaVia noted its Phase 2a study in 109 patients over 16 weeks showed direct hepatic activity, improved glucose metabolism, and a favorable safety and tolerability profile. The company will continue AI-driven exploration to refine indications and optimize vanoglipel's therapeutic profile.
MetaVia (Nasdaq: MTVA) closed an underwritten public offering on Jan 16, 2026, raising approximately $9.3 million gross, which reflects full exercise of the underwriter's over-allotment option. The offering included 3,005,574 common shares (or equivalents), 4,508,361 Series C warrants (5-year, $3.10 exercise) and 4,508,361 Series D warrants (2-year, $3.10 exercise, callable after a positive Phase 1b Part III DA-1726 data readout). If all warrants and pre-funded warrants are exercised for cash, future gross proceeds could reach approximately $28.0 million. Net proceeds are intended for working capital and continued clinical development of DA-1726 for obesity.
MetaVia (Nasdaq: MTVA) reported positive Phase 1b results for DA-1726 from an 8-week non-titrated 48 mg cohort, showing early and statistically significant metabolic effects by Day 54.
Key results: weight -9.1% (21.2 lbs), waist -9.8 cm (p=0.022), fasted glucose -12.3 mg/dL, and liver stiffness -23.7% (VCTE); no treatment-related discontinuations and mainly mild-to-moderate GI events. The company plans 16-week titration studies with results expected in Q4 2026.
MetaVia (Nasdaq: MTVA) will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference. Company business development and clinical team members will attend the event scheduled for January 8–10, 2026 at the Chateaux Deer Valley in Park City, Utah.
This participation highlights MetaVia's engagement with the cardiometabolic and clinical research community but does not include financial or clinical readouts in this announcement.
MetaVia (Nasdaq: MTVA) announced on December 22, 2025 that it received Nasdaq notice dated December 19, 2025 confirming the company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2).
The notice states MetaVia also satisfies all other applicable Nasdaq listing criteria and that the related listing matter has been closed on the Nasdaq Capital Market.
MetaVia (Nasdaq: MTVA) announced a 1-for-11 reverse stock split of its common stock, effective 5:00 p.m. ET on December 4, 2025, with trading on a split-adjusted basis beginning December 5, 2025.
The reverse split was authorized by stockholders June 30, 2025, and approved by the board at a 1-for-11 ratio to help the company comply with Nasdaq continued listing requirements. Outstanding shares will fall from approximately 25.4 million to 2.3 million, while the number of authorized shares remains 100 million. Conversion and exercise prices for restricted stock units, options and warrants will increase proportionally.
Any fractional shares will be rounded down and paid in cash based on the closing Nasdaq price on the last trading day before the split. The stock will continue to trade under the symbol MTVA and a new CUSIP will be 64132R503.
MetaVia (Nasdaq: MTVA) presented positive Phase 2a data for oral GPR119 agonist vanoglipel (DA-1241) in presumed MASH at AASLD 2025.
In a 16-week randomized, placebo-controlled trial of 109 patients, vanoglipel produced mean HbA1c reductions of –0.54%p (monotherapy) and –0.66%p (100 mg + DPP4i) at Week 16; early HbA1c drops were seen by Week 4. Treatment improved liver inflammation, steatosis (CAP), and liver stiffness (VCTE), lowered biomarkers of cell death, inflammation and fibrosis (CK18F/M30, hs-CRP, CCL2, TIMP1), and reduced pathogenic plasma lipids (glycerolipids DG36:4, TG52:4; glycerophospholipids PE38:4, PE38:5). Vanoglipel was well tolerated with no treatment-emergent discontinuations attributed to drug.
MetaVia (Nasdaq: MTVA) reported Q3 2025 results and a corporate update on Nov 6, 2025. Key clinical highlights include dosing the first patient in an 8-week, 48 mg MAD cohort of DA-1726 with top-line data expected by year-end 2025, Phase 1 results showing up to 6.3% mean body-weight reduction, up to 3.9-inch waist reduction, linear dose-proportional PK and an ~80-hour half-life supporting once-weekly dosing. Vanoglipel (DA-1241) Phase 2a showed reductions in liver fat, inflammation and fibrosis; full data to be presented at AASLD 2025. Financially, cash was $14.3M at Sept 30, 2025, expected to fund operations into 2026.
MetaVia (Nasdaq: MTVA) will present new Phase 1 and preclinical data on DA-1726 at ObesityWeek® 2025 (Nov 4-7, 2025). Phase 1 results after four weeks showed favorable safety, tolerability, linear dose-proportional PK with an approximate 80-hour half-life, and clinically meaningful weight loss without titration.
At the 32 mg dose participants had up to 6.3% weight reduction (mean 4.3% at Day 26) and waist decreases up to 3.9 inches. No serious adverse events or discontinuations were reported. Preclinical DIO mouse data showed comparable weight loss to pemvidutide and superior lipid reductions versus pemvidutide and tirzepatide, driven partly by increased energy expenditure.
MetaVia (Nasdaq: MTVA) announced an accepted poster presentation on Vanoglipel (DA-1241), a GPR119 agonist, at the AASLD Liver Meeting 2025 in Washington, D.C., November 7–11, 2025.
The poster reports results from a 16-week randomized placebo-controlled trial in presumed MASH patients assessing hepatoprotective effects through improvements in inflammation and liver metabolism. Presenting author is Rohit Loomba, M.D., MHSc.
Poster details: Poster 4012, Session: Monday Poster Presenters Hall Hour; Date: Monday, November 10, 2025; Time: 1:00–2:00 pm ET; Location: Convention Center Hall DE, Level 2. A copy will be posted in the Posters section of MetaVia's website after the presentation.
FAQ
What is the current stock price of MetaVia (MTVA)?
What is the market cap of MetaVia (MTVA)?
